Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Down 90.8% in October

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 34,300 shares, a decline of 90.8% from the October 15th total of 374,300 shares. Based on an average trading volume of 202,400 shares, the days-to-cover ratio is presently 0.2 days.

Chugai Pharmaceutical Stock Down 2.3 %

OTCMKTS CHGCY traded down $0.53 on Thursday, hitting $23.02. 136,439 shares of the company were exchanged, compared to its average volume of 128,623. The stock has a fifty day moving average of $23.75 and a 200-day moving average of $20.44. Chugai Pharmaceutical has a 12 month low of $14.52 and a 12 month high of $26.00.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.